TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ACCORDING TO THE RUSSIAN PART OF THE EUTOS POPULATION-BASED STUDY

Background. The European Population Register EUTOS for CML includes data on adult patients (n = 2904) diagnosed with Ph-positive (Ph+) and/or BCR-ABL1-positive (BCR-ABL1+) chronic myeloid leukemia (CML) in 20 European countries during the period from 2008 to December 2012. Russia took part in this study, having contributed 6.8 % of CML patients to the total number of patients in the Register.

Aim. To estimate long-term treatment outcomes in patients with newly diagnosed CML in the Russian Federation in comparison with the data obtained for a pan-European population cohort of patients.

Patients and methods. The cohort under study consisted of 197 patients from 6 Russia regions, all of whom were diagnosed with a Ph+ / BCR-ABL1 + CML during the period from October, 1, 2009 to December, 31, 2012. The patients’ median age was 50 (18–82) years, with men and women being represented in approximately equal proportions.

Results. In the first line, 97 % and 3 % of the patients received Imatinib and 2nd generation tyrosine kinase (TKI) inhibitors, respectively. The response dynamics was as follows: 12 months after the treatment, a complete cytogenetic response and a major molecular response were achieved in 40 % and 20 % of the patients. The overall survival (OS) and progression-free survival rates in patients in Russia following 12, 24 and 30 months were 93 %, 87 % and 84 %, and 92 %, 87 % and 87 %, respectively. In Russia, the study was prolonged. By 80 months of observation, the OS of patients in the chronic CML phase with a low and high risk of the disease progression had been 88 % and 56 %, respectively. In the acceleration phase, the 5-year overall survival rate was 39 %.

Conclusion. An analysis of treatment outcomes in CML patients in a population-based non-selected sample indicates an increase in the survival of CML patients. However, problematic aspects of the therapy have been identified, along with a need for intensification of the treatment in patients with an unfavourable CML prognosis.

1. Chereda B., Melo J.V. Natural course and biology of CML. Ann Hematol. 2015; 94(2): 107–121.

2. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. The Lancet. 2007; 370(9584): 342–50.

3. Baccarani M., Deininger M.W., Rosti G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6): 872–84.

4. Bower H., Bjorkholm M., Dickman P.W., et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology. 2016;34: 2851–7.

5. Kulikov S.M., Vinogradova O.Yu., Chelysheva E.Yu., et al. The incidence of chronic myeloid leukemia in 6 regions of Russia according to a population-based study of the Russian Federation. Terapevticheskiy arkhiv. 2014;86(7):24–30 (In Russian).

6. Hehlmann R., Grimwade D., Simonsson B., et al. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011; 96(1): 156–62.

7. Hoglund M., Sandin F., Hellstrom K., et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013; 122(7): 1284–92.

8. Kulikov S.M., Vinogradova O.Yu., Chelysheva E.Yu., et al. Analysis of age-related anomalies in the recorded incidence of patients with chronic myeloid leukemia. Gematologiya i transfuziologiya. 2014; 1: 99–100 (In Russian).

9. Hoffmann V.S., Baccarani M., Hasford J., et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015; 29(6): 1336–43.

10. Lazareva O.V., Turkina A.G., Chelysheva E.Yu., et al. Clinical and hematological characteristics of patients with chronic myeloid leukemia in modern conditions: results of the Russian part of the international multicenter prospective population study EUTOS Population-based CML Study. Klinicheskaya onkogematologiya. 2017; 10(1): 65–74 (In Russian). DOI: 10.21320 / 2500-2139-2017-10-1-65-74

11. Hoffmann V.S., Baccarani M., Hasford J., et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry Leukemia. 2017; 31(3): 593–601. DOI: 10.1038/leu.2016.246

12. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in «good risk» chronic granulocytic leukemia. Blood. 1984; 63(4): 789–99.

13. Hasford J., Baccarani M., Hoffmann V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011; 118(3): 686–92. DOI: 10.1182/blood-2010-12-319038

14. Pfirrmann M., Baccarani M., Saussele S., et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016; 30(1): 48–56.

15. Thielen N., Visser O., Ossenkoppele G., Janssen J. Chronic Myeloid Leukaemia in The Netherlands: a Population-Based Study on Incidence, Treatment and Survival in 3,585 Patients from 1989–2012. Eur J Haematol. 2016; 97(2): 145–54.

16. Storey S. Chronic myelogenous leukaemia market. Nat Rev Drug Discov. 2009; 8(6): 447–8.

17. Huang X., Cortes J., Kantarjian H. Estimation of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012; 118(12): 3123–7